ArticleCancers2025

Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab.

Tai-Chi Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.